GANX
Gain Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.92 / 10
Netural
Sentiment is neutral (5.92) while fund‑flow score is strong at 7.83, showing overall positive inflows but a negative Small‑cap trend. Analyst coverage is limited to one Strong Buy with a 25% historical win rate, and the stock has fallen 24.69%.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-19
InstitutionHC Wainwright & Co.
Times predicted4
Historical Win Rate25.0%
What is the analyst consensus for GANX?
- GANX holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.92/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
